soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 SELECT Trial

A 2-tailed P value of less than 0.05 was considered statistically significant in all analyses

Early launch trends appear encouraging, with insurance coverage expanding through major pharmacy benefit managers, supporting broader patient access

For those interested in exploring options, you can learn more about vitamin b12 injections for energy and how they might fit into your wellness routine

Description Additional information Description GHK-Cu is a research compound in lyophilized powder form for laboratory research, testing, and analytical applications

The rise of UPF consumption is now broadly seen as the key factor driving the obesity epidemic ( Figure 2 )